Member Info for potnak

Also. With your links, Just look at what we could get when we have a P3 asset plus 2 promising P2 assets.

Ah Afham. You made me feel all fuzzy :-). I'm not here to prove you or anyone else wrong. These links are great but most aren't pre-clinical. Most are P2 or P3 assets and without digging deeper, I suspect the companies already have assets worth hundreds of millions if not billions already. The fact is. unless there is insurmountable data to say otherwise. Most big pharma's will see how early safety trials pan out before committing the big bucks to a deal. I'm confident we will get there but in steps, starting with SRA737.

Hi Basser. I think Peel Hunt are on board to do what they do. They raise awareness or cash by way of institutional investment. Just look at the news page on their site. https://www.peelhunt.com/news-events/#news

See, this is the thing. In your example, Celtic, you and others here are David Icke. You are blinded by optimism and the belief that a massive rerate is imminent. When the reality is, very few transformational deals are made at the preclinical stage. Try and find one and post it here. Why would Sareum be any different? Posters here keep citing the Kymab deal of $1.5 billion that Michale Owen helped over the line. They never tell you that was a P2a asset though. I've been here a long time and i'm fully expecting to be here for a few more years yet. I believe we will get our big payout but the growth will be incremental starting with SRA737 rather than a non-regulatory notification of the CTA being approved. I don't care if this makes potential buyers not buy. I have my shares and i'm keeping hold of them until I don't.

I like to see all views here. I'd especially like to see the opinions of other investors who have invested in the sector before and have experience with how this plays out. I want to see some challenging of baseless claims that an imminent buyout is the only end game. Because the market clearly disagrees with that claim.

That's where I get my £2 billion guesstimate from, HBD. £2 billion combined for all three compounds by end of P2.

We know as of June 22, they haven't sold. No reason or volume since then to think they've sold either. Still think any budding researchers out there should focus on phama's with links to Belgium.

I do not need to believe in the science. I hope it works but for the sake of my investment. All I need to happen is a major pharma to belive it has potential. I hope to have sold my holding way before the chance we might fail a P3. Been there done that and it's not a nice feeling. I've always been positive about Sareum and very rarely negative. It just feels like we're all watching the Emperor ride past cheering away whilst a few others are telling us he doesn't have any clothes on. I'll get back in my box for a bit.

Yes, HBD. He could tweak the compound but not on 1801. Not without having to back through pre clinical again. 1801 is locked and loaded now..

We are past what John Reader can effectively bring to the table. We've chosen the indication we will attempt to progress. The science for SAR is done. The trials are just that. They are trials based on what we applied for, we don't get to tweak or change the compound. It's done. We're are now waiting for the trial to start, I'm not sure the CTA acknowledgment will do anything major to the SP, we will need a licence deal or data readout to do that. So right now I'd rather pin my hopes on Parker and Dr Owen negotiating a deal that adds some nesessary value to the company.

Posters can post whatever they want and they do. They can also buy and sell whenever they want and they do. It's when the 'science' is used to shout down any negative posts. There are a lot of posters here that use the science trope as a comfort blanket. That it is the be-all and end-all, the thing that will propel SAR to the moon, it isn't, the science isn't proven yet and it will be a long time before it will be. The corporate finance guys on the board will are the ones who make the deal and I hope they are doing their job right now. As for delays. The 'no delay due to covid' thing is the board gaslighting us. The fact is, the board told us in June 2019 that we should be heading to clinical trials in 2020. I make that a 2 year delay at least and if you bought in 2019 on the back of that RNS or others that came after it. You'd have reason to be a little negative about the whole thing. I am holding for gold but I will trade a few on the way. I don't usually agree with Warty, Utar and others because I know bio takes a long time. Problem is, it takes even longer if you introduce your own delays into it because of inexperience or lack of funds. We're past the science bit, make the deals.

I hope you are correct, Basser. However, I am prepared for the long Hall just in case.

Absolutely, Seawolf. I think Sareum will be a £2 billion company one day but there will be plenty of opportunities to trade or top slice on our way to 2 billion.

Yes, Basser. A proper discussion with all views considered is better for all of us. Your tox point is a good example. We can't say we have no tox issues until P1 is finished and the data is back, 2024, minimum, for that. Pretty sure the board can share early data with prospective partners though. It is my belief that this is what happened with SRA737. Sierra (Pronai) waited until some early tox data was in before doing the licencing deal. I think the same will happen with 1801, a licencing deal will come not long after the first patient is dosed.

I'll tell you where i am in my thinking. Not that my opinion counts any more or less than any other opinions but here it is anyway. I'm an LTH and have approx 50k Shares. I don't come to this board as much as I used, mainly because there is nothing new to see. We have some great scientific researchers here, posting some pretty compelling evidence on why our compounds 'should' make the grade. However, this feels like confirmation bias to me. Trying to convince yourself that you made the right call by holding the shares all these years. I'm not saying to stop with this, it's none of my business and if it genuinely helps you validate your decisions then fill your boots. Same with the huys who like to read and comment on the research posted. If it helps, go for it.

The likes of Utar, Aber, Warty and others are all LTH and they have valid points about the progress and timescales. However, this is where my position comes in.

No one is taking into account the delays we endured from 2019 until the present. back in 2019, my original cash-out time was 2022 based on what the board was telling us in 2018/19. We had several RNS's in 2019 stating we were aiming for clinical trials to start in 2020 and for whatever reason, here we are in 2022 and it's looking like it will be 2023 before the first patient is dosed. If we hadn't had delays we would have been through P1a/b and ready to start P2 and firmly in the buyout phase. Good that we are moving but we are effectively 2 years behind schedule and there is no magic catch-up button we can press. It is what it is. I have come to terms with this delay and have different expectations of when my cash out will be. Realistically, I think we are looking at 2024 before the big deal comes. The only caveat to that is the TYK2 approval news from last week. This might be the last opportunity for a major to buy a potential blockbuster compound on the cheap. If you want to wait for the big deal and are willing to take the risk then sitting on your hands is your only option.

SRA737 was CTA approved April 4th 2016, Trial started on May 31st and we got a licence on Sept 27th. A bit less than 6 months but enough time to get some early data to say its safe. The same timescale means end of Jan to mid Feb 2023 for licence news.

The 'August Statement' has been used, in the past as a substitute for actual news. Not a bad thing, I will add but it's just a regurgitated recap of what we already know. I agree the fact that we haven't got one probably means there is some news coming. We might get the recap statement in October after the CTA approval. We all have different opinions but mine, FWIW is that we will get the CTA RNS and maybe a start date for the trial but no licencing deal until there is some data back on the initial safety profile (we won't see the data). If the drug doesn't give the patient Bloaty Head Syndrome, we will get a licence. IMO there is no reason for any big pharma to carry the risk until they know it is safe. We might, might get something towards the end of this year but it could easily run into next year before early data is available to share with Partners.

Like this?
"woohoo! Boom, We have completed most of the preparatory work for the clinical trial and have built a robust data package to support our ongoing partnering activities for this asset. Subject to regulatory approval by MHRA, we look forward to advancing SDC-1801 into clinical development. Fill your boots lad's. Thus time in 3 years, we'll be millionaires, "

Sorry, *Maf'

There is no nuance with an RNS, as Naf said, facts only. In fact you can get into serious trouble if you mislead the market. My absolute biggest bugbear with share forums is posters expecting something different to what the company has told them is happening and then getting p*ssed off when the thing they were expecting doesn't happen. This board does it all the time. AGM and results notifications are fine examples. News will never be released at an AGM or the realise of financial results. Just sit back and be patient. I'm predicting we will still be sat here this time next year, waiting for P1 results to be released. However, we should be sitting at a higher share price because we will have a licence deal.

Nail on head in 5 words Mafuta.